On December 14, 2020, the FLCCC Alliance peer-reviewed paper Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID-19 has been published in the Journal of Intensive Care Medicine. The MATH+ protocol potentially offers a life-saving approach to the management of hospitalized COVID-19 patients. It offers an inexpensive combination of medicines with well-known safety profiles based on strong physiologic rationale and an increasing clinical evidence base.
... scientific studies that provide the medical evidence in support of the individual medical therapies that make up our MATH+ Hospital Treatment Protocol for Covid-19 (and in parts also our I-MASK+ Protocol):
In summary, based on the existing and cumulative body of evidence, we recommend the use of ivermectin in both prophylaxis and treatment for COVID-19. In the presence of a global COVID-19 surge, the widespread use of this safe, inexpensive, and effective intervention would lead to a drastic reduction in transmission rates and the morbidity and mortality in mild, moderate, and even severe disease phases.
A founding principle underlying our I-MASK+ and MATH+ treatment protocols is that they evolve in accordance with both emerging therapeutic trials evidence as well as new pathophysiologic insights. When sufficient supportive evidence for a new therapeutic against COVID-19 emerges, we first add these medicines as “optional” components until such a time when we can better clarify their additive or synergistic efficacy to the existing core therapies.
This is our recommended approach to COVID-19 based on the best (and most recent) literature. This is a highly dynamic topic; therefore, we will be updating the guideline as new information emerges. Please check on the FLCCC Alliance website for updated versions of this protocol.
This manuscript reviews the scientific and clinical rationale behind MATH+ based on published in-vitro, pre-clinical, and clinical data in support of each medicine, with a special emphasis of studies supporting their use in the treatment of patients with viral syndromes and COVID-19 specifically.
. In 2017, with the addition of intravenous hydroxycortisone (cortisol), ascorbic acid (vitamin C), and thiamine (vitamin B1) to standard sepsis care, Dr. Paul Marik found great success against sepsis, including septic shock. This became known as “HAT” therapy for sepsis, and was a starting point for the FLCCC Alliance in the battle against COVID-19. Given the complexity of COVID-19, the “HAT” therapy was quickly expanded to the “MATH+” protocol for the care of hospitalized COVID-19 patients.
Leading critical care specialists of the Front Line COVID19 Critical Care Alliance have developed MATH+ —a treatment protocol for critically ill COVID19 patients; and I-Mask+—a preventative and early outpatient COVID19 treatment protocol.